Biologics vs Biosimilars:Research and Development in Pharma
Microbioz India, July, 2019 Issue
Cover Story : “Biologics vs Biosimilars:Research and Development in Pharma"
23 July, 2019
Dear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring to you the July 2019 edition of Microbioz India magazine, supported by the cover story entitled “Biologics vs Biosimilars : Research and Development in Pharma” a review study on comperative study of Biosimilars and Biologics.A biosimilar is exactly what its name implies — it is a biologic that is “similar” to another biologic medicine (known as a reference product) which is already licensed by the U.S. Food and Drug Administration (FDA).
Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. In approving biosimilars, the FDA may require that manufacturers conduct a clinical study (or studies) sufficient to establish safety, purity or potency in one or more uses for which the reference product is licensed and the biosimilar seeks licensure.
Added to this, the current edition has a special featured guest article entitled “Take a look at Blood with analysis machines ” by maxon precision motor India Pvt Ltd. Includes product description with Blood analysis.Our blood is a fascinating fluid it transports oxygen and nutrients, fends off foreign objects and closes wounds. At least in normal cases some people, however, suffer from coagulation disorders. These cases are unpleasant for the patient and can have severe consequences – or even lead to death. This is why early detection of a blood disorder and the hunt for a cure are so important. This requires a lot of testing. We have the latest market research news and insightful product launches inside, collected from worldwide sources to keep you updated with what is going on in the industry.